CASI Pharmaceuticals, Inc. (CASIF): Total Assets
$25.65M
As of 2025-12-31
-35.6%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.65M | -52.2% | 2026-05-15, Balance as of period end |
| 2024-12-31 | $53.67M | -28.7% | 2026-05-15, Balance as of period end |
| 2023-12-31 | $75.27M | -21.8% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $96.23M | -30.4% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $138.30M | n/a | 2023-04-26, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $25.65M | -52.2% |
| Scynexis Inc (SCYX) | 2025-12-31 | $59.03M | -34.9% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $20.27M | -14.8% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $29.92M | -16.5% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $769.28M | -11.0% |
| Alumis Inc. (ALMS) | 2025-12-31 | $411.94M | +20.8% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $377.38M | -28.3% |
| Celularity Inc (CELU) | 2025-12-31 | $107.33M | -19.1% |
| uniQure N.V. (QURE) | 2025-12-31 | $824.91M | +48.2% |
Compare CASIF, SCYX, EVFM, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗